Bristol-Myers Squibb: Key Facts
Key Facts
Chief Executive Officer:
Lamberto Andreotti
New York City
Web Address:
NYSE Listing:
Net Sales:
$16.4 billion in 2013
R&D Investment:
$3.7 billion in 2013
2013 Largest-Selling Products:
ABILIFY®, $2.3 billion
SUSTIVA® franchise, $1.6 billion
REYATAZ®, $1.6 billion
BARACLUDE®, $1.5 billion
ORENCIA® $1.4 billion
SPRYCEL® $1.3 billion
YERVOY® $960 million
Selected Key Products:
ABILIFY® (aripiprazole)
ATRIPLA® (efavirenz / emtricitabine / tenofovir disoproxil fumarate)
BARACLUDE® (entecavir)
ELIQUIS® (apixaban)
ERBITUX® (cetuximab)
NULOJIX® (belatacept)
ORENCIA® (abatacept)
REYATAZ® (atazanavir sulfate)
SPRYCEL® (dasatinib)
SUSTIVA® (efavirenz)
YERVOY® (ipilimumab)
Principal Locations:
Worldwide Facilities

Please click on the product links to see the Full Prescribing Information for ABILIFY®, ATRIPLA®, BARACLUDE®, ELIQUIS®, ERBITUX®, NULOJIX®, ORENCIA®, PLAVIX®, REYATAZ®, SPRYCEL®, SUSTIVA®, and YERVOY®, including Boxed WARNINGS for ABILIFY®, ATRIPLA®, BARACLUDE®, ELIQUIS®, NULOJIX®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction and Boxed WARNINGS for ERBITUX® regarding infusion reactions and cardiopulmonary arrest.

February, 2014


You are leaving to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.